Tolvaptan filed for rare kidney disease in Japan
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical has submitted an approval application in Japan for its first-in-class oral vasopressin V2 receptor antagonist tolvaptan for the additional orphan indication of autosomal dominant polycystic kidney disease (ADPKD).